[Caution] not approved anywhere. keep posts descriptive.
not approved anywhere. keep posts descriptive. Not a hot take, just something I have not seen said plainly here.
Sent a vial to Medutest because there was almost nothing on file for this compound. 98.1% against a claimed 97.5%, and I posted it because the log needs entries.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Is there any independent purity data on this compound that you have seen?
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same recepto
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
nothing here is approved as a standalone product and research material is not for human use
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
The engineering problem was duration: native amylin is short-acting and aggregation-prone.
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
Correction: that is the combination programme, not the monotherapy readout.
Agreed, and the combination arms are where the interesting numbers actually live.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.
This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.
do not assume the dosing intuitions from the GLP-1 boards transfer
How many separate lots has anyone here tested?
do not assume the dosing intuitions from the GLP-1 boards transfer
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
satiety signalling rather than incretin signalling
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
- 1do not assume the dosing intuitions from the GLP-1 boards transfer6 comments in this branch · started by u/noor_ivaturi